Rett Syndrome and Fragile X Syndrome: Different Etiology With Common Molecular Dysfunctions
Rett syndrome (RTT) and Fragile X syndrome (FXS) are two monogenetic neurodevelopmental disorders with complex clinical presentations. RTT is caused by mutations in the Methyl-CpG binding protein 2 gene ( MECP2 ) altering the function of its protein product MeCP2. MeCP2 modulates gene expression by...
Saved in:
Published in: | Frontiers in cellular neuroscience Vol. 15; p. 764761 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Lausanne
Frontiers Research Foundation
19-11-2021
Frontiers Media S.A |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Rett syndrome (RTT) and Fragile X syndrome (FXS) are two monogenetic neurodevelopmental disorders with complex clinical presentations. RTT is caused by mutations in the Methyl-CpG binding protein 2 gene (
MECP2
) altering the function of its protein product MeCP2. MeCP2 modulates gene expression by binding methylated CpG dinucleotides, and by interacting with transcription factors. FXS is caused by the silencing of the
FMR1
gene encoding the Fragile X Mental Retardation Protein (FMRP), a RNA binding protein involved in multiple steps of RNA metabolism, and modulating the translation of thousands of proteins including a large set of synaptic proteins. Despite differences in genetic etiology, there are overlapping features in RTT and FXS, possibly due to interactions between MeCP2 and FMRP, and to the regulation of pathways resulting in dysregulation of common molecular signaling. Furthermore, basic physiological mechanisms are regulated by these proteins and might concur to the pathophysiology of both syndromes. Considering that RTT and FXS are disorders affecting brain development, and that most of the common targets of MeCP2 and FMRP are involved in brain activity, we discuss the mechanisms of synaptic function and plasticity altered in RTT and FXS, and we consider the similarities and the differences between these two disorders. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Edited by: Shuxin Li, Temple University, United States These authors have contributed equally to this work This article was submitted to Cellular Neuropathology, a section of the journal Frontiers in Cellular Neuroscience Reviewed by: Michael Telias, University of California, Berkeley, United States; Christina Gross, Cincinnati Children’s Hospital Medical Center, United States |
ISSN: | 1662-5102 1662-5102 |
DOI: | 10.3389/fncel.2021.764761 |